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Abstract
Neointima formation and vascular remodeling through vascular smooth muscle cell migration and proliferation
can limit the long-term success of coronary interventions, for example, in coronary artery bypass grafting
(CABG). Ex vivo gene therapy has the potential to reduce unnecessary cell proliferation and limit neointima
formation in vascular pathologies. To date, the species C adenovirus serotype 5 has been commonly used for
preclinical gene therapy; however, its suitability is potentially limited by relatively poor tropism for vascular
cells and high levels of preexisting immunity in the population. To avoid these limitations, novel species of
adenovirus are being tested; here we investigate the potential of adenovirus 49 (Ad49) for use in gene therapy.
Transduction of primary human vascular cells by a range of adenovirus serotypes was assessed; Ad49 dem-
onstrated highest transduction of both vascular smooth muscle and endothelial cells. Gene transfer with Ad49 in
vascular smooth muscle and endothelial cells was possible following short exposure times (< 1 hr) and with low
MOI, which is clinically relevant. Ex vivo delivery to surplus CABG tissue showed efficient gene transfer with
Ad49, consistent with the in vitro findings. Luminal infusion of Ad49GFP into intact CABG samples ex vivo
resulted in efficient vessel transduction. In addition, no seroprevalence rates to Ad49 were observed in a
Scottish cohort of patients from cardiovascular clinics, thus circumventing issues with preexisting immunity.
Our results show that Ad49 has tropism for vascular cells in vitro and ex vivo and demonstrate that Ad49 may be
an improved vector for local vascular gene therapy compared with current alternatives.
Introduction
Cardiovascular disease remains one of the leadingcauses of mortality worldwide.1 Use of gene therapy,
targeting myocardium and vascular cells, remains a promis-
ing strategy for treatment of a variety of cardiovascular
diseases. Efficient gene transfer to cardiomyocytes using
adeno-associated virus (AAV) vectors has been shown in
many preclinical models (reviewed in ref.2), and promising
results have been reported in the phase 2 CUPID clinical trial
overexpressing sarcoplasmic reticulum Ca2+ -ATPase (SER-
CA2a) via AAV-1 in patients with advanced heart failure.3
Outside the myocardium, targeting vascular cells for gene
therapy could be beneficial in reducing both cardiovascular
diseases, for example, angiogenesis associated with ischemic
disease and pathological vascular remodeling associated with
vein graft failure. Coronary revascularization procedures are
some of the most common major medical surgeries. In coro-
nary artery bypass grafting (CABG), a peripheral section of
vasculature, usually saphenous vein is used to bypass the oc-
cluded vessel in the coronary circulation. Following the pro-
cedure, the vessel undergoes a period of remodeling to adapt to
the increased blood flow and pressure in the arterial circula-
tion. However, excessive vascular smooth muscle cell
(VSMC) migration and proliferation and damaged endothe-
lium cause neointima formation and can limit the long-term
success of the graft; studies report that > 25% of grafts have
reduced patency after 4 years and up to 50% at 10 years.4
Reduction of neointima formation by gene delivery to the
vasculature is an attractive proposition to improve long-term
patency of CABG procedures and reduce the need for repeat
surgery. Unlike cardiomyocytes, only low levels of trans-
duction are possible in VSMCs or endothelial cells (ECs)
using AAVs.5,6 However, preclinical studies using adenovirus
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vectors have shown that gene delivery to the vasculature can
prevent neointima formation.7,8 Expression of therapeutic
proteins, including endothelial nitric oxide synthase (eNOS),9
inducible nitric oxide synthase (iNOS),10 tissue inhibitors of
metalloproteinases 1–3 (TIMPs 1–3),7,11,12 p53,13 and Nogo-
B,14 has been shown to enhance EC regeneration and/or re-
duce VSMC proliferation and migration, in turn reducing
neointima formation, in animal models of CABG. In fact,
CABG surgery may be particularly suited to gene therapy as
the clinical setting facilitates ex vivo gene transfer to the vein
before implantation. To date, the majority of gene therapy
strategies have used adenovirus serotype 5 (Ad5) as the gene
delivery vector. However, Ad5 transduces vascular cells rel-
atively poorly and high multiplicities of infection are required
to achieve therapeutic levels of transgene expression.15,16
Previous analysis of receptor expression on VSMCs and
ECs has shown only low levels of coxsackie and adenovirus
receptor (CAR),17 the primary Ad5 receptor, and no detect-
able expression in intact human vessels.18 Additionally, in
CABG, the time available for ex vivo gene transfer before
grafting is short, potentially less than 30min, further limit-
ing the gene delivery possible with Ad5. An added clinical
consideration of Ad5 use is the common prevalence of pre-
existing neutralizing antibodies in the population,19 up to
80% seroprevalence in some studies,20 which may reduce the
efficacy of transgene expression,21 although the effect of
preexisting neutralizing antibodies on adenovirus transduc-
tion in the CABG setting is unknown as gene transfer occurs
ex vivo. Together, these limitations of Ad5 suggest that, while
the vector may be suitable for human CABG gene therapy,
alternative vectors might provide improved opportunities.
To increase transgene expression in the vasculature,
pseudotyping of Ad5 has been shown to be effective.22
Several subgroup B adenoviruses, including Ad35, use CD46
as a receptor,23 which is relatively highly expressed on
VSMCs, and chimeric Ad5/Ad35 viruses show more efficient
gene transfer to the vasculature than Ad5.17 An alternative
strategy is exploitation of the natural tropism of novel Ad
serotypes. Subgroup D adenoviruses vary in receptor use and
tropism; some infect cells by binding CAR, while others use
CD4624 or sialic acid.25 However, the receptors for many
subgroup D adenoviruses have not been identified, and
therefore they may provide new vectors for gene therapy. An
additional clinical benefit is that species D adenoviruses are
reported to have low seroprevalence rates.24 Here we evalu-
ated a panel of adenoviruses and highlight the efficacy of
Ad49 as a vector for vascular gene therapy.
Materials and Methods
Cells and tissue
PER.C6 cells26 (kind gift from Jerome Custers, Crucell)
and HEK293 cells (human embryonic kidney: ATCC CRL-
1573) were used for viral propagation and cultured in Dul-
becco’s modified Eagle’s medium (DMEM; Invitrogen)
with 2mM L-glutamine (Invitrogen) and 10% fetal calf
serum (FCS; PAA Laboratories) with the addition of 10mM
MgCl2 (Sigma-Aldrich) for PER.C6 cells. Hep G2 (hepa-
tocellular carcinoma: ATCC HB-8065), A549 (human lung
carcinoma: ATCC CCL-185), and SKOV3 (human ovarian
carcinoma: ATCC HTB-77) cells were cultured in minimal
essential medium (MEM) or RPMI-1640 medium (Invitro-
gen), with 2mM L-glutamine, 10% FCS, and 1mM sodium
pyruvate (Sigma-Aldrich). Cells were maintained at 37C
and 5% CO2 with the exception of PER.C6 maintained in
10% CO2. Human saphenous vein segments were obtained
from patients, who gave informed consent, undergoing
CABG. Ethics permission was obtained from the West of
Scotland Research Ethics Committee 4 (reference number
10/S0704/60). Serum samples were obtained, with consent,
from patients attending cardiovascular disease clinics with
ethics permission from the West Glasgow Ethics Committee
1 (reference number S/0703/110).
Smooth muscle and EC isolation and culturing
VSMCs were isolated from human saphenous vein seg-
ments using the explant technique as previously described27
and cultured in SMC growth media 2 (PromoCell) with
addition of provided supplement mix, 10% FCS, and 2mM
L-glutamine. ECs were isolated from human saphenous vein
segments by collagenase digestion as previously described
and cultured in Large Vessel Endothelial Cell Basal Med-
ium (TCS CellWorks) with provided supplements and 20%
FCS. Primary cell lines were used between passage 3 and 6.
Recombinant adenoviral vectors
All recombinant adenoviruses described in this article
were kind gifts from Jerome Custers (Crucell); Ad5, Ad26,
Ad35, Ad48, and Ad49 are replication-incompetent E1/E3
deleted vectors constructed as described previously.28,29
Viruses were propagated in HEK293 or PER.C6, E1-
complementing cell lines and purified using CsCl gradients.
Viral recovery was quantified by microBCA assay (Ther-
moFisher) assuming that 1lg protein = 4 · 109 viral particles
(vp) and confirmed by nanosight measurement (Nanosight).
Infectious units (pfu) were quantified by end-point dilution
plaque assay.30
Transduction assays and neutralization assays
Cells were plated in 96-well format, 1 · 104 cells/well,
and incubated overnight. Cells were infected with 1000,
2500, 5000, or 10,000 vp/cell in 50ll serum-free media,
– hFX (8 lg/ml) where stated. Cells were incubated with
virus for 3 hr at 37C, unless otherwise stated; washed with
PBS; and maintained in standard medium until harvesting
with reporter lysis buffer (RLB; Promega) 48 hr postinfec-
tion. Luciferase activity was measured in cell lysates using a
luciferase assay (Promega) and protein concentrations were
calculated by BCA (ThermoFisher) assays were measured
using a Wallac Victor2 plate reader (PerkinElmer) and values
expressed as relative light units (RLU)/mg of protein. For
serum neutralization studies, transduction of Hep G2 cells
was carried out as above in the presence of 2.5% serum as
previously been shown to be optimum.31 Samples were
considered neutralizing if greater than 90% reduction in
transduction was seen in comparison to no serum control. To
determine GFP expression, cells were detached from the
culture vessel with 1xTE, washed, and quantified using a
flow-assisted cell sorter (FACS) Canto II flow cytometer
(Becton Dickinson) and FACS DIVA software. Viable cells
were gated by their FSC/SSC profiles, with a minimum of
10,000 gated events analyzed per sample. Results are
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expressed as percentage of positively stained cells per sam-
ple, from three independent samples analyzed in triplicate.
Ex vivo transduction of CABG tissue
Human saphenous vein tissue was trimmed to remove
excess periadventitial fat and divided into equal (*5mm)
sections before incubation with adenovirus: 1· 109 vp or PBS
in 500ll serum-free media for 1 hr at 37C. Tissue sections
were washed and cultured for a further 48 hr in SMC media.
Luciferase activity was analyzed using bioluminescence
quantification imaging (IVIS Spectrum; Caliper Life Sci-
ences) quantified as average radiance (photons per second per
centimeter squared per steradian). Human saphenous veins
were transduced by luminal delivery of adenoviruses as
previously described.11 Four- to six-centimeter segments of
vein were cannulated, and the luminal surface was exposed to
adenoviral vectors at 1· 1010 pfu/ml at physiological pressure
for 1 hr. Segments of vein were cultured for 3 days in DMEM
containing 30% FCS and antibiotics.
Immunohistochemistry
Immunohistochemistry was performed on 4lm para-
formaldehyde fixed sections. Following rehydration, heat-
induced antigen retrieval was performed with 10mM sodium
citrate buffer (pH 6) and sections were blocked in 15% goat
serum before incubation with primary antibodies: chicken
FIG. 1. Transduction of primary vascular cells. VSMCs (A) and ECs (B) were transduced with 10,000 vp/cell of adenovirus
for 3 hr at 37C. Cells were cultured for a further 48 hr before analysis of luciferase transgene expression was performed.
Representative images (20· ) of VSMCs following transduction of 1,000 (1k), 5,000 (5k), or 10,000 (10k) vp/cell Ad5 or
Ad49–GFP are shown in (C). FACS analysis of GFP expression 48hr posttransduction in hVSMCS (D) and ECs (E). Data are
mean+SE compared with Ad5 by one-way ANOVA with Dunnett’s post-hoc analysis or Student’s t-test; **p< 0.01,
***p< 0.001. Ad5, adenovirus serotype 5; ECs, endothelial cells; vp, viral particles; VSMCs, vascular smooth muscle cell.
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anti-gfp (Abcam), mouse anti-smooth muscle actin (Dako),
and rabbit anti-von Willebrand factor (Dako). Fluorescent
secondary antibodies were used for detection, goat anti-
chicken 488, anti-rabbit 546, and anti-mouse 647 (Invitrogen),
and slides weremounted with ProLongGoldAntifade Reagent
with DAPI (Invitrogen). Images were acquired using a Zeiss
LSM510 confocal imaging system (Carl Zeiss).
Statistics
In vitro data presented are representative from a minimum
of three separate experiments with at least three experi-
mental replicates per group unless otherwise stated. Trans-
duction graphs are displayed with a log scale as appropriate,
and for these experiments data were log transformed be-
fore analysis. Statistical significance was calculated using
ANOVA or Student’s t-test; p< 0.05 was considered statis-
tically significant.
Results
Ad49 tropism for human vascular cells in vitro
To initially evaluate vector tropism for vascular cells, the
transduction efficiency of four serotypes of adenovirus was
evaluated in primary VSMCs and ECs, in comparison to the
commonly used vector Ad5. Previous reports have demon-
strated relatively high transduction of vascular cells by
Ad35,17 therefore acting as a positive control for efficient
transduction in this study. The other three Ad serotypes
chosen belonged to subgroup D and have not been investi-
gated in the terms of vascular cell transduction. Ad-
ditionally, low seroprevalence to these Ad serotypes has
been found24,32 in serum samples from sub-Saharan Africa.
First, transduction efficiency was assessed using vectors
expressing luciferase. In comparison to Ad5, VSMCs trans-
duced with Ad48 and Ad49 had significantly higher lucif-
erase activity (Fig. 1A). Similarly, Ad49 also had the highest
luciferase activity following infection of ECs (Fig. 1B). To
enable visualization of transgene expression in vascular cells,
an Ad49 vector expressing GFP was generated. VSMCs and
ECs were transduced with a range of viral titers and fluo-
rescence assessed microscopically, and representative images
of VSMCs are shown in Fig. 1C. GFP expression was further
analyzed using FACS, and VSMCs (Fig. 1D) and ECs (Fig.
1E) transduced with Ad49 had higher GFP expression
compared with Ad5. Collectively, these data demonstrate
that Ad49 can efficiently transduce primary human vascular
cells.
To investigate more general selectivity, Ad49 gene
transfer was assessed in other cell lines with different re-
ceptor profiles (Supplementary Fig. S1; Supplementary Data
are available online at www.liebertpub.com/hum).
Transduction of VSMC and ECs in short time periods
In the context of CABG surgery, the time available for
gene transfer is limited, and therefore rapid and efficient
transduction is important. To investigate the potential for
Ad49 to transduce cells following minimal, clinically rele-
vant contact times, exposure of Ad5 or Ad49 to VSMCs and
ECs was reduced to between 10 and 60min. In comparison
to Ad5, higher luciferase activity was detected in VSMCs
(Fig. 2A) and ECs (Fig. 2B) transduced with Ad49 at all
time points tested, down to just 10min exposure. Further-
more, efficient gene transfer was possible when both low
titers of 1,000 vp/cell and high titers of 10,000 vp/cell were
used for short incubation times (Fig. 2A and B).
Ex vivo gene transfer to intact saphenous vein
The above data demonstrate Ad49 as an efficient vector
for gene transfer to vascular cells in vitro. To further in-
vestigate the potential for clinical use, transduction of sur-
plus CABG tissue was undertaken. First, whole vessels were
incubated with Ad vectors and luciferase activity was
quantified using an IVIS imaging system. Consistent with
the in vitro data, luciferase activity was detected in tissue
exposed to Ad49 at significantly increased levels to control
(Fig. 3A). Follow-up studies exposing only the luminal
surface of the tissue to Ad49GFP were performed in CABG
samples from three patients. Cells positive for GFP co-
localized with those stained for von Willebrand factor, a
marker of ECs (Fig. 3B). Sections were stained throughout
the length of vein exposed to Ad49GFP, and positive GFP
staining was detected in ECs throughout the vessel.
Preexisting immunity to Ad49
The use of adenovirus vectors in a clinical setting may be
limited by preexisting immunity,33 depending on the route
of administration and target tissue, although this may not be
problematic where ex vivo gene transfer is being utilized. To
determine the seroprevalence of Ad49 in a clinically rele-
vant population, serum samples were collected from 103
FIG. 2. Transduction of cells with short exposure times.
VSMCs (A) and ECs (B) were infected with 1,000 and
10,000 vp/cell of adenovirus for 10–60min. Cells were
cultured for a further 48 hr before analysis of luciferase
transgene expression was performed. Data are mean + SE
compared with equivalent Ad5 with Student’s t-test;
*p< 0.05, **p < 0.01, ***p < 0.001.
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patients in Glasgow cardiovascular clinics. Presence of
neutralizing antibodies was determined by preincubating
Ad5 or Ad49 with 2.5% serum, recognized as an optimal
dilution,24,31 before transduction of HepG2 cells (Fig. 4A).
Samples were considered neutralizing if transduction was
reduced by 90% compared with virus alone, previously
shown to be ideal for studying neutralization patterns of
Ads.22,34 Ad5 was neutralized by 31% (32/103) of serum
samples, while none of the 103 serum samples reduced
Ad49 cell transduction by 90% (Fig. 4B). Further analysis
found that 1 serum sample could reduce Ad49 transduction
by 50%, while an additional 16 samples could reduce Ad5
transduction to between 10% and 50% of control.
Discussion
The aim of this study was to identify an Ad serotype
suitable for use as a vascular gene therapy vector: assessing
efficacy in vitro and ex vivo and determining any sero-
prevalence in the population that may limit clinical use. For
the first time we report the natural tropism of Ad49, a
species D adenovirus, for vascular cells demonstrating ef-
ficient gene transfer in primary vascular cells and human
CABG tissues.
Previous vascular gene therapy studies have used high
concentrations of Ad5 for gene transfer. Ad5 transduces
cells through engagement with CAR and further internali-
zation using integrins.35,36 The limited expression of CAR
on vascular cells presumably leads to the requirement for
high concentrations of Ad5. The in vitro results presented
here demonstrate that Ad49 is able to transduce both
VSMCs and ECs, resulting in higher reporter gene activity
than Ad5. We demonstrated that gene transfer with an al-
ternative reporter gene, GFP, was more efficient with Ad49
than Ad5 over a range of viral concentrations. Ad35 and
pseudotyping of Ad5 with Ad35 fiber have previously been
proposed as efficient vascular gene therapy vectors because
of high expression of their receptor CD46 on vascular
cells.17 Interestingly, these results suggest that Ad49 can
transduce vascular cells with greater efficiency than Ad35
and that lower concentrations of vector than have been
previously used may be sufficient in vivo.
Furthermore, we tested the efficacy of Ad49 following
short exposure times on cells because of the limited clinical
time available for gene transfer. In comparison to Ad5, lu-
ciferase activity was 100 times higher following Ad49
transduction of VSMC and ECs and still efficient with low
multiplicity of infection and only 10min incubation with
FIG. 3. Ex vivo transduc-
tion of human coronary ar-
tery bypass graft tissue.
Surplus coronary artery by-
pass grafting (CABG) tissue
was cut into equal sections
and incubated with 1 · 109 vp
Ad49LUC or PBS for 1 hr at
37C.Media was replacedwith
20%and sampleswere cultured
for a further 48hr. Luciferase
activity was analyzed using the
IVIS system and quantified as
average radiance (A). Data are
mean+SEM.Luminal dwell of
Ad49GFP (1·1010 pfu/ml)
was performed for 1 hr at room
temperature on surplus saphe-
nous vein.Vesselswere opened
longitudinally and cultured for
72hr. GFP expression was vi-
sualized using immunohisto-
chemistry (B). Sections of 4lm
were stained with antibodies
against a-smooth muscle actin
(SMA, purple), vonWillebrand
factor (VWF, red), and GFP
(green) or relevant IgG con-
trols, and visualized using
confocal microscopy at 10· .
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cells. The transduction efficiency of Ad49 in the cell lines,
A549, SKOV3, and Hep G2, was similar or less than that of
Ad5. This further supports the superior efficiency of the
vector in vascular cells compared with Ad5, which is not
evident in all cell types. It will be important to determine the
primary receptor used by Ad49. The in vitro data led us to
speculate that Ad49 could be a useful vector for vascular
gene transfer, using lower concentrations and incubation
times than is optimal with Ad5.
To confirm the clinical relevance of the Ad49 vector,
further gene transfer experiments were carried out ex vivo in
CABG tissue. While primary cells are a good tool for
modeling in vitro, their phenotype can alter in culture in
isolation from normal neighboring cell types.37 First, whole
sections of CABG tissue were incubated with Ad49, con-
firming that efficient vascular transduction of intact tissues
was possible. To recreate the clinical situation and deter-
mine exactly which cell types were being transduced ex
vivo, we delivered Ad49 to the lumen of saphenous vein.
The luminal surface of the vessel will experience the dra-
matic changes in flow and pressure following grafting into
the arterial circulation and as such these cells may be the
optimal clinical target for preventing neointima formation.
Efficient gene transfer of GFP was detected in samples from
three different patients. Interestingly, transgene expression
co-localized with positive staining for the EC marker von
Willebrand factor. This is consistent with the transduction
data in primary cultured ECs from similar samples; how-
ever, no gene transfer was detected in the medial smooth
muscle cell layer. Previous reports have shown Ad5 gene
transfer to VSMC.12 The reason for the differences in cell
specificity ex vivo is currently unclear but may be because of
receptor expression distribution and levels and/or differences
in surgical approaches to graft harvest and treatment. It has
been previously suggested that Ad49 can bind to CD46,28
which is highly expressed on ECs.17 Additionally, over the
last decade surgeons have adopted a no-touch technique for
harvest of saphenous veins that has been shown to reduce
SMC activation and damage to ECs.38 The change in harvest
method, maintaining a complete endothelial layer, could
contribute to the distribution of infected cells.
Gene transfer to ECs is clinically relevant as, in addi-
tion to control of VSMC proliferation, ECs often get dam-
aged during vascular procedures and re-establishing a healthy
endothelium can reduce neointima formation.39–41 Despite
the new surgical techniques designed to preserve the en-
dothelium, CABG failure is still a clinical problem. De-
livery of eNOS42 and vascular endothelial growth factor
(VEGF)43 to ECs has been shown to reduce neointima
formation in animal models. Furthermore, delivery of
Ad49 vectors encoding secreted transgenes such as p5313
or A2044 could be used to reduce the VSMC proliferation
associated with neointima formation. EC gene therapy is
also beneficial in other disease settings: to promote re-
vascularization of ischemic tissue and reduced angiogen-
esis in cancer. Efficient gene transfer has thus far been
limited in angiogenic gene therapy (reviewed in ref.45),
Ad49 may also be a useful vector in this setting, and fur-
ther research is required.
Clinical use of viral vectors can be limited by preexisting
immunity. In the CUPID clinical trial, almost 50% of pa-
tients had to be excluded because of AAV-neutralizing an-
tibody titers of > 1/2.46 Preexisting immunity to Ad5 has
been demonstrated in the general population.47 As such to
be considered for clinical use, new vectors must have a more
favorable neutralization profile. This does not diminish the
use of Ad5 in a vein graft gene therapy setting, but these
findings may impact gene transfer settings where contact to
the blood may be relevant, such as intravascular adminis-
tration. The sera from 31% of patients tested in this study
could neutralize Ad5, while none were able to reduce
transduction with Ad49. Here we specifically used serum
from a potential target population for vascular gene therapy,
patients of a cardiovascular clinic. One previous study has
also reported low levels of preexisting immunity to Ad49 in
sera taken from four continents.28 Consistent with a previ-
ous study,28 there was no cross-reactive Ad5/Ad49-specific
immunity observed in the serum cohort in this study.
Taken together, the data demonstrate that Ad49-based
vectors have great potential for CABG gene therapy appli-
cation in the clinic. Further investigation using Ad49 in
preclinical CABG models is warranted.
Acknowledgments
This work was funded by a British Heart Foundation Project
Grant (PG/12/19/29455). AHB is supported by a Royal So-
ciety Wolfson Merit Award. We thank Nicola Britton, Gregor
Aitchison, and Zaki Rabhan for their technical assistance. We
would also like to thank Jerome Custers and Taco Uil (Crucell,
Leiden, The Netherlands) for supplying the PER.C6 cells and
adenovirus strains used in this study.
Author Disclosure Statement
No competing financial interests exist.
FIG. 4. Preexisting immunity to Ad49 in patients under-
going CABG. Transduction assays were carried out in the
presence of serum samples from 103 patients from Glasgow
Cardiovascular Clinics, and each bar represents 1 patient
(A). Samples with 90% or greater reduction in adenovirus-
mediated luciferase expression, compared with virus only
control, were considered neutralizing (B).
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